Prosecution Insights
Last updated: April 19, 2026

Nippon Shinyaku Co. Ltd.

6 pending office actions

Portfolio Summary

6
Total Pending OAs
3
Final Rejections
3
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18504781 Composition Comprising Antisense Oligonucleotide and Use Thereof for Treatment of Duchenne Muscular Dystrophy ARIETI, RUTH SOPHIA 1635 Final Rejection Nov 08, 2023
18288057 METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND GALSTER, SAMUEL LEONARD 1693 Non-Final OA Oct 24, 2023
18284941 THERAPEUTIC AGENT FOR GAIT DISTURBANCE MCMILLIAN, KARA RENITA 1623 Non-Final OA Sep 29, 2023
17788551 ANTITUMOR DRUG FOR USE IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITOR RZECZYCKI, PHILLIP MATTHEW 1625 Final Rejection Jun 23, 2022
17418203 METHOD FOR INDUCING MUSCULAR CELLS USING CELLS IN SPOT URINE REGLAS, GILLIAN CHELSEA 1632 Final Rejection Jun 24, 2021
17293929 1,3,4-OXADIAZOLONE COMPOUND AND PHARMACEUTICAL ELENISTE, PIERRE PAUL 1622 Non-Final OA May 14, 2021

Managing Nippon Shinyaku Co. Ltd.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month